SABCS 2025 – Roche mounts its early breast cancer challenge
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
Janux lets the genie out of the bottle
A more comprehensive dataset on JANX007 sends the group’s stock down.
ASH 2025 preview – Kelonia gets a late-breaking coup
An in vivo Car-T produced a 100% response rate – in three patients.
Novartis trips over the Hippo
The company discontinues its Yap/TEAD inhibitor IAG933 owing to lack of tolerability and efficacy.
ESMO 2025 – Sanofi takes aim at Lutathera
But Perspective sinks again.
ESMO 2025 – Novartis looks for Pluvicto prostate Addition
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
BeOne cashes in its Imdelltra royalty
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
FDA doubles down on overall survival
New draft guidance could see the agency getting ever stricter.
